These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 15366327)

  • 1. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
    Niopas I; Daftsios AC; Nikolaidis N
    Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
    Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
    Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
    Niopas I; Daftsios AC; Nikolaidis N
    Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
    Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
    Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.
    Kim YH; Choi KS; Kam SH; Lee KH; Park JS
    Arzneimittelforschung; 2012 Dec; 62(12):576-82. PubMed ID: 23093481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
    Chen J; Jiang XG; Cai L; Lu W; Gao KP; Shi ZQ; Zhang QZ
    Arzneimittelforschung; 2004; 54(4):203-6. PubMed ID: 15146932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
    Metzner JE; Buchberger D; Häring N; Läuter J
    Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
    Luo WX; Zhang YD; Shen JP; Ding Y; Huang DK; Luo JP; Qiu J; Jiang ZH; Peng JH; Sheng LS
    Zhongguo Yao Li Xue Bao; 1999 Oct; 20(10):951-6. PubMed ID: 11270999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Bonn R; Fritschi E; Jaeger H
    Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
    Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H
    J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
    Gandini R; Cunietti E; Assereto R; Castoldi D; Tofanetti O; Baggio E
    Arzneimittelforschung; 1987 Jul; 37(7):836-9. PubMed ID: 3675680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
    Baxter T; Eadie CJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
    Skutta T; Böttcher B; Brandt L
    Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.